Suchergebnisse - "Klein, Christian"

PubPharm (30)

1

A pivotal decade for bispecific antibodies?

enthalten in: mAbs | 2024

von Surowka, M. | Klein, C.

ErratumIn: MAbs. 2024 Jan-Dec;16(1):2335597. - PMID 38546818

2

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

enthalten in: Journal for immunotherapy of cancer | 2021

von Leclercq, G. | Haegel, H. | Schneider, A. | +12

3

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

enthalten in: mAbs | 2021

von Waldhauer, I. | Gonzalez-Nicolini, V. | Freimoser-Grundschober, A. | +26

4

Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids : Comparative Analysis of 2D and 3D Cell Culture Models

enthalten in: Molecules (Basel, Switzerland) | 2021

von Hundsberger, H. | Stierschneider, A. | Sarne, V. | +9

5

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001) : a multicentre, dose escalation and expansion phase 1 study

enthalten in: The Lancet. Haematology | 2020

von Michot, J. | Bouabdallah, R. | Vitolo, U. | +17

CommentIn: Lancet Haematol. 2020 Sep;7(9):e627-e629. - PMID 32758435

6

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

enthalten in: Journal of immunology (Baltimore, Md. : 1950) | 2018

von Palazzo, A. | Herter, S. | Grosmaire, L. | +13

7

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

enthalten in: Haematologica | 2018

von Herter, S. | Herting, F. | Muth, G. | +9

8

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies

enthalten in: Blood | 2017

von Valgardsdottir, R. | Cattaneo, I. | Klein, C. | +3

CommentIn: Blood. 2017 May 11;129(19):2596-2597. - PMID 28495923

9

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

enthalten in: Advances in therapy | 2017

von Tobinai, K. | Klein, C. | Oya, N. | +1

10

Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)

enthalten in: European journal of haematology | 2016

von Herting, F. | Herter, S. | Friess, T. | +6